Biostimulators and Treatment Planning

Hyaluronic acid gives you a result the patient can see in the mirror before they leave. Biostimulators give you a result they notice six months later and cannot quite explain. One sells itself. The other builds a face.

This chapter covers the three biostimulatory classes an aesthetic practitioner will realistically use — poly-L-lactic acid, calcium hydroxylapatite, and autologous platelet preparations — and then does the more important thing: it puts them in order alongside everything else in the toolkit.

WHAT BIOSTIMULATION ACTUALLY IS
You are not injecting volume. You are commissioning collagen.

A biostimulator is a controlled injury. You implant a material the body must respond to; the response is a subclinical foreign-body reaction that recruits fibroblasts and lays down type I and type III collagen. The volume is not in the syringe — the volume is what the patient grows.

• Onset is slow — six weeks minimum, three to six months for the full effect.
• The effect is diffuse, not sculptural. Biostimulators improve quality and generalised support; they do not build a jaw angle.
• They are not reversible. Hyaluronidase does nothing. This is the single most important clinical distinction from HA and it governs where you may safely use them.
• Patient selection is everything. Older, thinner, laxer skin responds well. Young patients seeking definition do not need this.

POLY-L-LACTIC ACID (SCULPTRA)
Nothing happens for weeks. That is the product working.

• Mechanism: PLLA microparticles are gradually hydrolysed, driving a sustained fibroblast response over months. Neocollagenesis is the entire effect; the injected volume disappears within days.
• Reconstitution: modern practice favours higher dilution than the original licence — commonly 8–10 ml of sterile water, with 1–2 ml of lidocaine added shortly before use. Reconstitute at least two hours ahead, and preferably the day before, to ensure full hydration and reduce nodule risk.
• Plane: subdermal and supraperiosteal only. Never intradermal. Dermal placement is the classic cause of visible papules.
• Technique: cross-hatched linear retrograde threads or fanning with a 25G cannula. Keep moving. Do not bolus.
• Avoid entirely in the periorbital region, the lips, and the immediate perioral area.
• Course: typically two to three sessions at six to eight week intervals, one to two vials per session.
• Aftercare: the "five-five-five" rule — massage for five minutes, five times a day, for five days. Patients who do not massage get nodules.
• Duration: up to 24 months.

CALCIUM HYDROXYLAPATITE (RADIESSE)
Volume now, collagen later, or hyperdiluted for skin alone.

• Mechanism: dual action. Immediate volume from the carboxymethylcellulose gel carrier, then sustained collagen and elastin stimulation from the calcium hydroxylapatite microspheres as the carrier resorbs.
• Undiluted: a high-G′ volumising agent for subdermal and supraperiosteal use — jawline, chin, temples, hands. Very high projection.
• Diluted 1:1 or 1:2 with lidocaine or saline: a subdermal skin-tightening agent for the lower face, neck, décolletage, arms, abdomen and knees. This is where CaHA has become genuinely distinctive.
• Hyperdilution (1:4 or greater): a broad biostimulatory field treatment for skin laxity, delivered subdermally by cannula.
• Absolute exclusions: lips, tear trough, glabella, and any high-vascular-risk zone — because it cannot be dissolved.
• Duration: 12–18 months, with the collagen benefit persisting beyond the product.

PRP AND PRF
Modest, honest, and consistently oversold.

• PRP — platelet-rich plasma. Blood is centrifuged with an anticoagulant; the platelet-rich fraction is injected, releasing growth factors as a bolus.
• PRF — platelet-rich fibrin. No anticoagulant, slower spin. The result is a fibrin scaffold that releases growth factors over seven to ten days rather than in a burst, and can be prepared as a liquid or as an injectable gel.
• Indications: skin quality, periorbital hollowing and crepiness (where PRF is one of the few safe volumising options), scarring, and androgenetic alopecia.
• Course: three sessions at four-week intervals, then maintenance at six to twelve months.
• Honest counselling: the evidence base is heterogeneous and preparation protocols vary enormously between systems. Results are real but modest, and it is a quality treatment rather than a volume treatment.
• Advantage: autologous, no allergy risk, no foreign-body reaction, safe in the periorbital region where nothing else is.

BIOSTIMULATOR COMPARISON TABLE
What each one does, and how long it takes to do it.

TREATMENT PLANNING — THE SEQUENCING RULE
Structure before surface. Always.

Sequencing is the part of aesthetic medicine that separates a practitioner from a service provider. A patient with a fixed budget and a face full of problems does not need everything. They need the correct first thing.

Sequencing rules that matter within a session

• Toxin before filler in the same region, ideally two weeks before. The mentalis is the standard example: relax it first, then judge how much chin projection is actually required.
• Never inject filler through an area treated with a biostimulator in the same session — the planes and massage requirements conflict.
• Do not combine energy devices and filler on the same day. Leave two weeks either side.
• Photograph and reassess at two weeks before adding anything. Judging a result on the day of treatment is judging oedema.

BUILDING A TWELVE-MONTH PLAN
What a year of a face should actually look like.

COMBINING BIOSTIMULATORS WITH HA AND TOXIN
Canvas, contour, and the forces that undo both.

• HA and biostimulator on the same day: acceptable if they are in different regions and different planes. Never stack them in the same pocket.
• Toxin and biostimulator on the same day: acceptable; different targets, different planes.
• Biostimulator over existing HA: allow the HA to settle for at least four weeks, and record clearly what is where — a future practitioner needs to know what is dissolvable.
• Dissolving in a face containing biostimulator: hyaluronidase removes only the HA. Warn the patient that the residual contour is not reversible.
• Record-keeping: maintain a facial map per patient with product, plane, date and volume. This is the single most useful document you will ever produce for a colleague managing a complication.

Final Word

Patients do not come back for the product. They come back for a plan they can see themselves inside. A twelve-month sequence, honestly costed and honestly staged, converts a one-off syringe into a decade of clinical relationship — and produces a face that ages well rather than one that has been repeatedly rescued.